Definium's LSD therapy significantly reduces generalised anxiety in Phase 3 trial

Definium Therapeutics announced that its LSD-based therapy, the pill DT120, significantly eased symptoms of generalised anxiety disorder in a Phase 3 trial involving 214 patients, who received either a single dose or a placebo. This is the company's second major clinical success in two months, following a Phase 3 win for the same treatment in major depression.